{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:52:10Z","timestamp":1775296330373,"version":"3.50.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11255-018-2047-y","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T23:19:03Z","timestamp":1543965543000},"page":"265-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The effect of chronic kidney disease on lipid metabolism"],"prefix":"10.1007","volume":"51","author":[{"given":"Neris","family":"Dincer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuncay","family":"Dagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baris","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"issue":"7","key":"2047_CR1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1681\/ASN.2016050562","volume":"28","author":"B Thomas","year":"2017","unstructured":"Thomas B et al (2017) Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol 28(7):2167\u20132179","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2047_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5455\/medarh.2016.70.191-192","volume":"70","author":"SV Zubovic","year":"2016","unstructured":"Zubovic SV et al (2016) Chronic kidney disease and lipid disorders. Med Arch 70(3):191\u2013192","journal-title":"Med Arch"},{"issue":"4","key":"2047_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(16)00033-4","volume":"4","author":"R Vanholder","year":"2016","unstructured":"Vanholder R et al (2016) Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diab Endocrinol 4(4):360\u2013373","journal-title":"Lancet Diab Endocrinol"},{"issue":"9931","key":"2047_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","volume":"383","author":"A Ortiz","year":"2014","unstructured":"Ortiz A et al (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383(9931):1831\u20131843","journal-title":"Lancet"},{"key":"2047_CR5","doi-asserted-by":"crossref","unstructured":"Lamprea-Montealegre JA et al (2018) Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease. Heart","DOI":"10.1136\/heartjnl-2017-312794"},{"issue":"2","key":"2047_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000488816","volume":"46","author":"MC Bulbul","year":"2018","unstructured":"Bulbul MC et al (2018) Disorders of lipid metabolism in chronic kidney disease. Blood Purif 46(2):144\u2013152","journal-title":"Blood Purif"},{"key":"2047_CR7","first-page":"182","volume":"6","author":"LH Huang","year":"2015","unstructured":"Huang LH, Elvington A, Randolph GJ (2015) The role of the lymphatic system in cholesterol transport. Front Pharmacol 6:182","journal-title":"Front Pharmacol"},{"issue":"2","key":"2047_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3803\/EnM.2016.31.2.223","volume":"31","author":"A Ossoli","year":"2016","unstructured":"Ossoli A, Pavanello C, Calabresi L (2016) High-density lipoprotein, lecithin: cholesterol acyltransferase, and atherosclerosis. Endocrinol Metab (Seoul) 31(2):223\u2013229","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"2047_CR9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/01.ASN.0000046962.43220.8A","volume":"14","author":"T Miida","year":"2003","unstructured":"Miida T et al (2003) LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 14(3):732\u2013738","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2047_CR10","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/ndt\/gft080","volume":"28","author":"T Speer","year":"2013","unstructured":"Speer T, Zewinger S, Fliser D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28(10):2456\u20132463","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2047_CR11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/gerona\/61.12.1262","volume":"61","author":"G Florvall","year":"2006","unstructured":"Florvall G, Basu S, Larsson A (2006) Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci 61(12):1262\u20131266","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"2047_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","volume":"153","author":"H Moradi","year":"2009","unstructured":"Moradi H et al (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153(2):77\u201385","journal-title":"Transl Res"},{"issue":"4","key":"2047_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5414\/CNP74273","volume":"74","author":"H Moradi","year":"2010","unstructured":"Moradi H et al (2010) Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease\u2014response to antioxidant therapy. Clin Nephrol 74(4):273\u2013281","journal-title":"Clin Nephrol"},{"issue":"7","key":"2047_CR14","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1093\/ndt\/gfr795","volume":"27","author":"ON Goek","year":"2012","unstructured":"Goek ON et al (2012) Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant 27(7):2839\u20132847","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2047_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-018-0771-z","volume":"17","author":"X Zhan","year":"2018","unstructured":"Zhan X et al (2018) Apolipoprotein B\/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids Health Dis 17(1):117","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2047_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2014.02.006","volume":"234","author":"JA Lamprea-Montealegre","year":"2014","unstructured":"Lamprea-Montealegre JA et al (2014) Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study. Atherosclerosis 234(1):42\u201346","journal-title":"Atherosclerosis"},{"issue":"4","key":"2047_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nm1211","volume":"11","author":"C Wolfrum","year":"2005","unstructured":"Wolfrum C, Poy MN, Stoffel M (2005) Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 11(4):418\u2013422","journal-title":"Nat Med"},{"key":"2047_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.atherosclerosis.2018.06.815","volume":"275","author":"IM Sorensen","year":"2018","unstructured":"Sorensen IM et al (2018) Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis 275:304\u2013311","journal-title":"Atherosclerosis"},{"issue":"1","key":"2047_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11255-016-1466-x","volume":"49","author":"A Gluba-Brzozka","year":"2017","unstructured":"Gluba-Brzozka A et al (2017) Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients? Int Urol Nephrol 49(1):155\u2013164","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"2047_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/1570161114666161003093032","volume":"15","author":"M Rysz-Gorzynska","year":"2017","unstructured":"Rysz-Gorzynska M, Gluba-Brzozka A, Banach M (2017) High-density lipoprotein and low-density lipoprotein subfractions in patients with chronic kidney disease. Curr Vasc Pharmacol 15(2):144\u2013151","journal-title":"Curr Vasc Pharmacol"},{"issue":"11","key":"2047_CR21","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/01.ATV.0000146325.93749.a8","volume":"24","author":"BF Asztalos","year":"2004","unstructured":"Asztalos BF et al (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24(11):2181\u20132187","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12A","key":"2047_CR22","doi-asserted-by":"publisher","first-page":"5L","DOI":"10.1016\/S0002-9149(00)01461-2","volume":"86","author":"PO Kwiterovich Jr","year":"2000","unstructured":"Kwiterovich PO Jr (2000) The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86(12A):5L\u201310L","journal-title":"Am J Cardiol"},{"issue":"6","key":"2047_CR23","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.kint.2017.05.020","volume":"92","author":"KB Rubinow","year":"2017","unstructured":"Rubinow KB et al (2017) Kidney function is associated with an altered protein composition of high-density lipoprotein. Kidney Int 92(6):1526\u20131535","journal-title":"Kidney Int"},{"key":"2047_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12944-015-0129-8","volume":"14","author":"X Xiong","year":"2015","unstructured":"Xiong X et al (2015) The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis 14:127","journal-title":"Lipids Health Dis"},{"issue":"8","key":"2047_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","volume":"127","author":"M Riwanto","year":"2013","unstructured":"Riwanto M et al (2013) Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127(8):891\u2013904","journal-title":"Circulation"},{"issue":"1","key":"2047_CR26","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1038\/s41598-017-02601-7","volume":"7","author":"M Luo","year":"2017","unstructured":"Luo M et al (2017) ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci Rep 7(1):2312","journal-title":"Sci Rep"},{"issue":"11","key":"2047_CR27","doi-asserted-by":"publisher","first-page":"e78670","DOI":"10.1371\/journal.pone.0078670","volume":"8","author":"M Rocha","year":"2013","unstructured":"Rocha M et al (2013) Association of serum retinol binding protein 4 with atherogenic dyslipidemia in morbid obese patients. PLoS ONE 8(11):e78670","journal-title":"PLoS ONE"},{"issue":"5","key":"2047_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000176534","volume":"29","author":"J Axelsson","year":"2009","unstructured":"Axelsson J et al (2009) Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. Am J Nephrol 29(5):447\u2013453","journal-title":"Am J Nephrol"},{"issue":"8","key":"2047_CR29","first-page":"12251233","volume":"13","author":"K Wang","year":"2018","unstructured":"Wang K et al (2018) Alteration of HDL Protein Composition with Hemodialysis Initiation. Clin J Am Soc Nephrol 13(8):1225\u20131233","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2047_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.atherosclerosis.2015.05.037","volume":"241","author":"I Sutter","year":"2015","unstructured":"Sutter I et al (2015) Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis 241(2):539\u2013546","journal-title":"Atherosclerosis"},{"key":"2047_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2018.01.037","volume":"270","author":"R Maeba","year":"2018","unstructured":"Maeba R et al (2018) Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: a cross-sectional study in chronic kidney disease patients. Atherosclerosis 270:102\u2013109","journal-title":"Atherosclerosis"},{"key":"2047_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fphar.2015.00243","volume":"6","author":"B Levkau","year":"2015","unstructured":"Levkau B (2015) HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front Pharmacol 6:243","journal-title":"Front Pharmacol"},{"issue":"4","key":"2047_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI200418004","volume":"113","author":"JR Nofer","year":"2004","unstructured":"Nofer JR et al (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113(4):569\u2013581","journal-title":"J Clin Invest"},{"issue":"6\u20137","key":"2047_CR34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/hsz-2014-0192","volume":"396","author":"N Prufer","year":"2015","unstructured":"Prufer N, Kleuser B, van der Giet M (2015) The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality. Biol Chem 396(6\u20137):573\u2013583","journal-title":"Biol Chem"},{"issue":"49","key":"2047_CR35","doi-asserted-by":"publisher","first-page":"37457","DOI":"10.1074\/jbc.M605823200","volume":"281","author":"T Kimura","year":"2006","unstructured":"Kimura T et al (2006) Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 281(49):37457\u201337467","journal-title":"J Biol Chem"},{"issue":"2","key":"2047_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/cvr\/cvp070","volume":"82","author":"K Sattler","year":"2009","unstructured":"Sattler K, Levkau B (2009) Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 82(2):201\u2013211","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2047_CR37","doi-asserted-by":"publisher","first-page":"e12866","DOI":"10.1111\/eci.12866","volume":"48","author":"JW Brinck","year":"2018","unstructured":"Brinck JW et al (2018) High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate. Eur J Clin Invest 48(2):e12866","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"2047_CR38","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","volume":"59","author":"ND Vaziri","year":"2001","unstructured":"Vaziri ND, Liang K, Parks JS (2001) Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 59(6):2192\u20132196","journal-title":"Kidney Int"},{"issue":"5","key":"2047_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/joim.12290","volume":"277","author":"L Calabresi","year":"2015","unstructured":"Calabresi L et al (2015) Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med 277(5):552\u2013561","journal-title":"J Intern Med"},{"issue":"10","key":"2047_CR40","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1177\/0003319718780041","volume":"69","author":"M Miljkovic","year":"2018","unstructured":"Miljkovic M et al (2018) Association of dyslipidemia, oxidative stress, and inflammation with redox status in VLDL, LDL, and HDL lipoproteins in patients with renal disease. Angiology 69(10):861\u2013870","journal-title":"Angiology"},{"key":"2047_CR41","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/gene\/5446 . Accessed 24 Nov 2018"},{"key":"2047_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.biochi.2016.10.010","volume":"132","author":"DA Chistiakov","year":"2017","unstructured":"Chistiakov DA et al (2017) Paraoxonase and atherosclerosis-related cardiovascular diseases. Biochimie 132:19\u201327","journal-title":"Biochimie"},{"issue":"10","key":"2047_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1161\/CIRCRESAHA.111.300581","volume":"112","author":"T Umemoto","year":"2013","unstructured":"Umemoto T et al (2013) Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 112(10):1345\u20131354","journal-title":"Circ Res"},{"issue":"6","key":"2047_CR44","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0027-9684(15)30368-0","volume":"103","author":"ND Vaziri","year":"2011","unstructured":"Vaziri ND et al (2011) Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc 103(6):524\u2013533","journal-title":"J Natl Med Assoc"},{"issue":"5","key":"2047_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1681\/ASN.2011070668","volume":"23","author":"T Weichhart","year":"2012","unstructured":"Weichhart T et al (2012) Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23(5):934\u2013947","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2047_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/cvr\/cvs089","volume":"94","author":"M Tolle","year":"2012","unstructured":"Tolle M et al (2012) High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94(1):154\u2013162","journal-title":"Cardiovasc Res"},{"issue":"10","key":"2047_CR47","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jdiacomp.2017.07.005","volume":"31","author":"JY Mao","year":"2017","unstructured":"Mao JY et al (2017) Serum amyloid A enrichment impairs the anti-inflammatory ability of HDL from diabetic nephropathy patients. J Diabetes Complications 31(10):1538\u20131543","journal-title":"J Diabetes Complications"},{"issue":"6","key":"2047_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrneph.2012.41","volume":"8","author":"GH Heine","year":"2012","unstructured":"Heine GH et al (2012) Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 8(6):362\u2013369","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"2047_CR49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1161\/CIRCULATIONAHA.112.000682","volume":"127","author":"A Ganda","year":"2013","unstructured":"Ganda A et al (2013) Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation 127(9):988\u2013996","journal-title":"Circulation"},{"issue":"9","key":"2047_CR50","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1161\/ATVBAHA.114.304172","volume":"34","author":"KS Rogacev","year":"2014","unstructured":"Rogacev KS et al (2014) Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14 + + CD16 + monocyte counts that predict cardiovascular events in chronic kidney disease. Arterioscler Thromb Vasc Biol 34(9):2120\u20132127","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2047_CR51","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3109\/07853890.2016.1168935","volume":"48","author":"Y Zhang","year":"2016","unstructured":"Zhang Y et al (2016) Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann Med 48(5):305\u2013312","journal-title":"Ann Med"},{"issue":"11","key":"2047_CR52","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.hlc.2016.02.023","volume":"25","author":"MS Cetin","year":"2016","unstructured":"Cetin MS et al (2016) Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ 25(11):1077\u20131086","journal-title":"Heart Lung Circ"},{"issue":"8","key":"2047_CR53","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s11255-014-0730-1","volume":"46","author":"M Kanbay","year":"2014","unstructured":"Kanbay M et al (2014) Monocyte count\/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 46(8):1619\u20131625","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2047_CR54","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","volume":"38","author":"T Speer","year":"2013","unstructured":"Speer T et al (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38(4):754\u2013768","journal-title":"Immunity"},{"issue":"20","key":"2047_CR55","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/eurheartj\/ehx118","volume":"38","author":"S Zewinger","year":"2017","unstructured":"Zewinger S et al (2017) Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J 38(20):1597\u20131607","journal-title":"Eur Heart J"},{"issue":"11","key":"2047_CR56","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1681\/ASN.2013111212","volume":"25","author":"R Shroff","year":"2014","unstructured":"Shroff R et al (2014) HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol 25(11):2658\u20132668","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2047_CR57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0022-2275(20)38540-0","volume":"29","author":"TA Musliner","year":"1988","unstructured":"Musliner TA, Michenfelder HJ, Krauss RM (1988) Interactions of high density lipoproteins with very low and low density lipoproteins during lipolysis. J Lipid Res 29(3):349\u2013361","journal-title":"J Lipid Res"},{"issue":"3","key":"2047_CR58","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1159\/000490686","volume":"43","author":"A Cwiklinska","year":"2018","unstructured":"Cwiklinska A et al (2018) Progression of chronic kidney disease affects HDL impact on lipoprotein lipase (LPL)-mediated VLDL lipolysis efficiency. Kidney Blood Press Res 43(3):970\u2013978","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"2047_CR59","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1681\/ASN.2013050482","volume":"25","author":"S Zewinger","year":"2014","unstructured":"Zewinger S et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25(5):1073\u20131082","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2047_CR60","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/ndt\/gfu022","volume":"29","author":"H Moradi","year":"2014","unstructured":"Moradi H et al (2014) Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant 29(8):1554\u20131562","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2047_CR61","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.2215\/CJN.00730116","volume":"11","author":"B Bowe","year":"2016","unstructured":"Bowe B et al (2016) High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans. Clin J Am Soc Nephrol 11(10):1784\u20131793","journal-title":"Clin J Am Soc Nephrol"},{"key":"2047_CR62","doi-asserted-by":"crossref","unstructured":"Chang TI et al. (2018) Inverse association between serum non-high-density lipoprotein cholesterol levels and mortality in patients undergoing incident hemodialysis. J Am Heart Assoc 7(12):e009096","DOI":"10.1161\/JAHA.118.009096"},{"issue":"43","key":"2047_CR63","first-page":"3007","volume":"36","author":"S Zewinger","year":"2015","unstructured":"Zewinger S et al (2015) Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 36(43):3007\u20133016","journal-title":"Eur Heart J"},{"key":"2047_CR64","volume-title":"Endotext","author":"KR Feingold","year":"2000","unstructured":"Feingold KR, Grunfeld C (2000) Introduction to lipids and lipoproteins. In: De Groot LJ et al (eds) Endotext. MDText.com, Inc., South Dartmouth (MA)"},{"key":"2047_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2017.07.003","volume":"263","author":"D Shiffman","year":"2017","unstructured":"Shiffman D et al (2017) LDL subfractions are associated with incident cardiovascular disease in the Malmo Prevention Project Study. Atherosclerosis 263:287\u2013292","journal-title":"Atherosclerosis"},{"issue":"1","key":"2047_CR66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11154-016-9402-z","volume":"18","author":"MR Hager","year":"2017","unstructured":"Hager MR, Narla AD, Tannock LR (2017) Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord 18(1):29\u201340","journal-title":"Rev Endocr Metab Disord"},{"key":"2047_CR67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.yjmcc.2015.03.016","volume":"84","author":"KC Chang","year":"2015","unstructured":"Chang KC et al (2015) Increased LDL electronegativity in chronic kidney disease disrupts calcium homeostasis resulting in cardiac dysfunction. J Mol Cell Cardiol 84:36\u201344","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"2047_CR68","doi-asserted-by":"publisher","first-page":"H265","DOI":"10.1152\/ajpheart.00509.2016","volume":"312","author":"TC Yang","year":"2017","unstructured":"Yang TC, Chang PY, Lu SC (2017) L5-LDL from ST-elevation myocardial infarction patients induces IL-1beta production via LOX-1 and NLRP3 inflammasome activation in macrophages. Am J Physiol Heart Circ Physiol 312(2):H265\u2013H274","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2047_CR69","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cardiores.2005.09.009","volume":"68","author":"D Li","year":"2005","unstructured":"Li D, Mehta JL (2005) Oxidized LDL, a critical factor in atherogenesis. Cardiovasc Res 68(3):353\u2013354","journal-title":"Cardiovasc Res"},{"issue":"13","key":"2047_CR70","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1096\/fj.99-0986com","volume":"14","author":"C Napoli","year":"2000","unstructured":"Napoli C et al (2000) Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J 14(13):1996\u20132007","journal-title":"FASEB J"},{"issue":"10","key":"2047_CR71","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1525-1497.2004.40049.x","volume":"19","author":"DE Weiner","year":"2004","unstructured":"Weiner DE, Sarnak MJ (2004) Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 19(10):1045\u20131052","journal-title":"J Gen Intern Med"},{"key":"2047_CR72","doi-asserted-by":"publisher","first-page":"507265","DOI":"10.1155\/2015\/507265","volume":"2015","author":"A Tavridou","year":"2015","unstructured":"Tavridou A et al (2015) Association of plasma adiponectin and oxidized low-density lipoprotein with carotid intima-media thickness in diabetic nephropathy. J Diabetes Res 2015:507265","journal-title":"J Diabetes Res"},{"issue":"2","key":"2047_CR73","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/0886022X.2011.641515","volume":"34","author":"EC Samouilidou","year":"2012","unstructured":"Samouilidou EC et al (2012) Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail 34(2):160\u2013164","journal-title":"Ren Fail"},{"issue":"4","key":"2047_CR74","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1542-4758.2012.00687.x","volume":"16","author":"S Ribeiro","year":"2012","unstructured":"Ribeiro S et al (2012) Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodial Int 16(4):481\u2013490","journal-title":"Hemodial Int"},{"issue":"2","key":"2047_CR75","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0021-9150(96)05842-X","volume":"124","author":"V Anber","year":"1996","unstructured":"Anber V et al (1996) Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124(2):261\u2013271","journal-title":"Atherosclerosis"},{"issue":"1","key":"2047_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/ATVBAHA.107.154989","volume":"28","author":"D Mohty","year":"2008","unstructured":"Mohty D et al (2008) Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28(1):187\u2013193","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2047_CR77","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","volume":"34","author":"RC Hoogeveen","year":"2014","unstructured":"Hoogeveen RC et al (2014) Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 34(5):1069\u20131077","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2047_CR78","doi-asserted-by":"publisher","first-page":"1273042","DOI":"10.1155\/2017\/1273042","volume":"2017","author":"EA Ivanova","year":"2017","unstructured":"Ivanova EA et al (2017) Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev 2017:1273042","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"2047_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12882-016-0358-8","volume":"17","author":"H Shen","year":"2016","unstructured":"Shen H et al (2016) Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients. BMC Nephrol 17(1):143","journal-title":"BMC Nephrol"},{"issue":"9","key":"2047_CR80","first-page":"1431","volume":"60","author":"D Sonmez","year":"2014","unstructured":"Sonmez D et al (2014) Is there a relationship between small, dense LDL and lipoprotein\u2013associated phospholipase A2 mass in dialysis patients? Clin Lab 60(9):1431\u20131437","journal-title":"Clin Lab"},{"issue":"9","key":"2047_CR81","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1194\/jlr.R200004-JLR200","volume":"43","author":"KK Berneis","year":"2002","unstructured":"Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43(9):1363\u20131379","journal-title":"J Lipid Res"},{"issue":"12","key":"2047_CR82","doi-asserted-by":"publisher","first-page":"e116386","DOI":"10.1371\/journal.pone.0116386","volume":"9","author":"GS Sharma","year":"2014","unstructured":"Sharma GS, Kumar T, Singh LR (2014) N-homocysteinylation induces different structural and functional consequences on acidic and basic proteins. PLoS ONE 9(12):e116386","journal-title":"PLoS ONE"},{"issue":"2","key":"2047_CR83","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jcb.20069","volume":"92","author":"G Ferretti","year":"2004","unstructured":"Ferretti G et al (2004) Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 92(2):351\u2013360","journal-title":"J Cell Biochem"},{"issue":"7","key":"2047_CR84","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1464-5491.2006.01809.x","volume":"23","author":"G Ferretti","year":"2006","unstructured":"Ferretti G et al (2006) Homocysteinylation of low-density lipoproteins (LDL) from subjects with Type 1 diabetes: effect on oxidative damage of human endothelial cells. Diabet Med 23(7):808\u2013813","journal-title":"Diabet Med"},{"issue":"3","key":"2047_CR85","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000319012","volume":"32","author":"A Zinellu","year":"2010","unstructured":"Zinellu A et al (2010) Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease. Am J Nephrol 32(3):242\u2013248","journal-title":"Am J Nephrol"},{"issue":"1","key":"2047_CR86","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejps.2012.05.006","volume":"47","author":"A Zinellu","year":"2012","unstructured":"Zinellu A et al (2012) LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. Eur J Pharm Sci 47(1):117\u2013123","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"2047_CR87","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.numecd.2015.04.001","volume":"25","author":"L Nicola De","year":"2015","unstructured":"De Nicola L et al (2015) Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: multicenter prospective study in Italy. Nutr Metab Cardiovasc Dis 25(8):756\u2013762","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2047_CR88","first-page":"8","volume":"6","author":"L Visconti","year":"2016","unstructured":"Visconti L et al (2016) Lipid disorders in patients with renal failure: role in cardiovascular events and progression of chronic kidney disease. J Clin Transl Endocrinol 6:8\u201314","journal-title":"J Clin Transl Endocrinol"},{"issue":"3","key":"2047_CR89","doi-asserted-by":"publisher","first-page":"c214","DOI":"10.1159\/000329509","volume":"119","author":"RG Bowden","year":"2011","unstructured":"Bowden RG et al (2011) Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients. Nephron Clin Pract 119(3):c214\u20139","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"2047_CR90","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M, Improving global outcomes lipid guideline Development Work Group (2014) KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85(6):1303\u20131309","journal-title":"Kidney Int"},{"issue":"1","key":"2047_CR91","first-page":"BC01","volume":"11","author":"RR Phukan","year":"2017","unstructured":"Phukan RR, Goswami RK (2017) Unusual dyslipidemia in patients with chronic kidney diseases. J Clin Diagn Res 11(1):BC01\u2013BC04","journal-title":"J Clin Diagn Res"},{"issue":"4 Suppl 1","key":"2047_CR92","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1053\/ajkd.2001.27393","volume":"38","author":"T Shoji","year":"2001","unstructured":"Shoji T et al (2001) Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38(4 Suppl 1):S30\u2013S33","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2047_CR93","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10157-011-0549-3","volume":"16","author":"ND Vaziri","year":"2012","unstructured":"Vaziri ND et al (2012) Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol 16(2):238\u2013243","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2047_CR94","first-page":"59","volume":"20","author":"V Blaton","year":"2009","unstructured":"Blaton V (2009) 8. dyslipidemia at chronic renal failure. EJIFCC 20(1):59\u201366","journal-title":"EJIFCC"},{"issue":"11","key":"2047_CR95","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1177\/039139880703001107","volume":"30","author":"GA Kaysen","year":"2007","unstructured":"Kaysen GA (2007) Hyperlipidemia in chronic kidney disease. Int J Artif Organs 30(11):987\u2013992","journal-title":"Int J Artif Organs"},{"issue":"1","key":"2047_CR96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000469714","volume":"42","author":"X Xie","year":"2017","unstructured":"Xie X et al (2017) Association of very low-density lipoprotein cholesterol with all-cause and cardiovascular mortality in peritoneal dialysis. Kidney Blood Press Res 42(1):52\u201361","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"2047_CR97","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1194\/jlr.M011163","volume":"52","author":"EM Ooi","year":"2011","unstructured":"Ooi EM et al (2011) Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J Lipid Res 52(4):794\u2013800","journal-title":"J Lipid Res"},{"issue":"2","key":"2047_CR98","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MED.0000000000000136","volume":"22","author":"AB Kohan","year":"2015","unstructured":"Kohan AB (2015) Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 22(2):119\u2013125","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"12","key":"2047_CR99","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11883-017-0697-3","volume":"19","author":"NA Rocha","year":"2017","unstructured":"Rocha NA et al (2017) ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep 19(12):62","journal-title":"Curr Atheroscler Rep"},{"key":"2047_CR100","unstructured":"GA K (2006) Dyslipidemia in chronic kidney disease: causes and consequences. Kidney Int 70:S55\u2013S58"},{"issue":"3","key":"2047_CR101","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1515\/CCLM.2005.050","volume":"43","author":"L Selmeci","year":"2005","unstructured":"Selmeci L et al (2005) Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clin Chem Lab Med 43(3):294\u2013297","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2047_CR102","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5507\/bp.2005.009","volume":"149","author":"M Skvarilova","year":"2005","unstructured":"Skvarilova M et al (2005) Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149(1):83\u201387","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"2","key":"2047_CR103","doi-asserted-by":"publisher","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","volume":"290","author":"ND Vaziri","year":"2006","unstructured":"Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290(2):F262\u2013F272","journal-title":"Am J Physiol Renal Physiol"},{"key":"2047_CR104","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/IJNRD.S101808","volume":"10","author":"I Mikolasevic","year":"2017","unstructured":"Mikolasevic I et al (2017) Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 10:35\u201345","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"6","key":"2047_CR105","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1046\/j.1523-1755.2003.00019.x","volume":"63","author":"T Hirano","year":"2003","unstructured":"Hirano T et al (2003) Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 63(6):2171\u20132177","journal-title":"Kidney Int"},{"issue":"8","key":"2047_CR106","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/jch.12758","volume":"18","author":"O Turak","year":"2016","unstructured":"Turak O et al (2016) The Role of plasma triglyceride\/high-density lipoprotein cholesterol ratio to predict new cardiovascular events in essential hypertensive patients. J Clin Hypertens (Greenwich) 18(8):772\u2013777","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"47","key":"2047_CR107","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S et al (2004) NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279(47):48865\u201348875","journal-title":"J Biol Chem"},{"issue":"2","key":"2047_CR108","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154\u2013156","journal-title":"Nat Genet"},{"issue":"1","key":"2047_CR109","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jacl.2016.10.005","volume":"11","author":"M Morena","year":"2017","unstructured":"Morena M et al (2017) Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism. J Clin Lipidol 11(1):87\u201393","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2047_CR110","first-page":"69","volume":"25","author":"SP McCormick","year":"2004","unstructured":"McCormick SP (2004) Lipoprotein(a): biology and clinical importance. Clin Biochem Rev 25(1):69\u201380","journal-title":"Clin Biochem Rev"},{"issue":"4","key":"2047_CR111","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","volume":"59","author":"JC Hopewell","year":"2018","unstructured":"Hopewell JC, Haynes R, Baigent C (2018) The role of lipoprotein (a) in chronic kidney disease. J Lipid Res 59(4):577\u2013585","journal-title":"J Lipid Res"},{"key":"2047_CR112","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12882-015-0122-5","volume":"16","author":"J Lin","year":"2015","unstructured":"Lin J et al (2015) Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol 16:130","journal-title":"BMC Nephrol"},{"issue":"12","key":"2047_CR113","doi-asserted-by":"publisher","first-page":"e114397","DOI":"10.1371\/journal.pone.0114397","volume":"9","author":"J Lin","year":"2014","unstructured":"Lin J et al (2014) Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS ONE 9(12):e114397","journal-title":"PLoS ONE"},{"key":"2047_CR114","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijcard.2015.12.007","volume":"205","author":"H Konishi","year":"2016","unstructured":"Konishi H et al (2016) Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol 205:50\u201353","journal-title":"Int J Cardiol"},{"issue":"9","key":"2047_CR115","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.amjcard.2015.02.011","volume":"115","author":"MA Guerraty","year":"2015","unstructured":"Guerraty MA et al (2015) Relation of aortic valve calcium to chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study). Am J Cardiol 115(9):1281\u20131286","journal-title":"Am J Cardiol"},{"issue":"6","key":"2047_CR116","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth PP et al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397\u20131408","journal-title":"Kidney Int"},{"issue":"5","key":"2047_CR117","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/joneph\/22.5.598","volume":"22","author":"M Kanbay","year":"2009","unstructured":"Kanbay M et al (2009) Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol 22(5):598\u2013609","journal-title":"J Nephrol"},{"issue":"10","key":"2047_CR118","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"CT Trialists","year":"2016","unstructured":"Trialists CT (2016) C., et al., Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4(10):829\u2013839","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2047_CR119","doi-asserted-by":"crossref","unstructured":"Ferro CJ et al. (2018) Lipid management in patients with chronic kidney disease. Nat Rev Nephrol","DOI":"10.1038\/s41581-018-0072-9"},{"issue":"9784","key":"2047_CR120","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181\u20132192","journal-title":"Lancet"},{"key":"2047_CR121","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijcard.2018.05.041","volume":"268","author":"Y Fukumoto","year":"2018","unstructured":"Fukumoto Y (2018) Impact of statin-ezetimibe combination in chronic kidney disease. Int J Cardiol 268:36\u201337","journal-title":"Int J Cardiol"},{"issue":"5","key":"2047_CR122","doi-asserted-by":"publisher","first-page":"e006886","DOI":"10.1136\/bmjopen-2014-006886","volume":"5","author":"YL Yan","year":"2015","unstructured":"Yan YL et al (2015) High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open 5(5):e006886","journal-title":"BMJ Open"},{"issue":"2","key":"2047_CR123","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacl.2017.01.001","volume":"11","author":"CM Chung","year":"2017","unstructured":"Chung CM et al (2017) Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol 11(2):422\u2013431 e2","journal-title":"J Clin Lipidol"},{"key":"2047_CR124","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy237","author":"CP Walther","year":"2018","unstructured":"Walther CP et al (2018) Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfy237","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2047_CR125","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238\u2013248","journal-title":"N Engl J Med"},{"issue":"5","key":"2047_CR126","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2215\/CJN.07161009","volume":"5","author":"KE Chan","year":"2010","unstructured":"Chan KE et al (2010) Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clin J Am Soc Nephrol 5(5):856\u2013866","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2047_CR127","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1468-6708-6-9","volume":"6","author":"B Fellstrom","year":"2005","unstructured":"Fellstrom B et al (2005) Effect of rosuvastatin on outcomes in chronic haemodialysis patients\u2014design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6(1):9","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"3","key":"2047_CR128","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/157016109788340712","volume":"7","author":"VG Athyros","year":"2009","unstructured":"Athyros VG et al (2009) Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention. Curr Vasc Pharmacol 7(3):264\u2013266","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"2047_CR129","doi-asserted-by":"publisher","first-page":"e0170017","DOI":"10.1371\/journal.pone.0170017","volume":"12","author":"EY Cho","year":"2017","unstructured":"Cho EY et al (2017) Efficacy of statin treatment in early-stage chronic kidney disease. PLoS ONE 12(1):e0170017","journal-title":"PLoS ONE"},{"issue":"6","key":"2047_CR130","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5527\/wjn.v1.i6.184","volume":"1","author":"R Scarpioni","year":"2012","unstructured":"Scarpioni R et al (2012) Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins. World J Nephrol 1(6):184\u2013194","journal-title":"World J Nephrol"},{"issue":"8","key":"2047_CR131","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-139-8-200310210-00011","volume":"139","author":"EM Balk","year":"2003","unstructured":"Balk EM et al (2003) Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139(8):670\u2013682","journal-title":"Ann Intern Med"},{"issue":"3","key":"2047_CR132","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1159\/000064083","volume":"92","author":"C Hottelart","year":"2002","unstructured":"Hottelart C et al (2002) Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92(3):536\u2013541","journal-title":"Nephron"},{"issue":"11","key":"2047_CR133","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0828-282X(06)70310-5","volume":"22","author":"R McPherson","year":"2006","unstructured":"McPherson R et al (2006) Canadian Cardiovascular Society position statement\u2013recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22(11):913\u2013927","journal-title":"Can J Cardiol"},{"issue":"20","key":"2047_CR134","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","volume":"60","author":"M Jun","year":"2012","unstructured":"Jun M et al (2012) Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 60(20):2061\u20132071","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2047_CR135","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.clinthera.2013.06.013","volume":"35","author":"DL Weinstein","year":"2013","unstructured":"Weinstein DL et al (2013) A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. Clin Ther 35(8):1186\u20131198","journal-title":"Clin Ther"},{"issue":"Suppl 7","key":"2047_CR136","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","volume":"4","author":"B Kasiske","year":"2004","unstructured":"Kasiske B et al (2004) Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4(Suppl 7):13\u201353","journal-title":"Am J Transplant"},{"issue":"6","key":"2047_CR137","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/toxins10060237","volume":"10","author":"R Vanholder","year":"2018","unstructured":"Vanholder R et al. (2018) Deleting death and dialysis: conservative care of cardio-vascular risk and kidney function loss in chronic kidney disease (CKD). Toxins (Basel). 10(6):237","journal-title":"Toxins (Basel)"},{"issue":"9","key":"2047_CR138","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3109\/0886022X.2010.510231","volume":"32","author":"KS Hassan","year":"2010","unstructured":"Hassan KS et al (2010) Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail 32(9):1031\u20131035","journal-title":"Ren Fail"},{"key":"2047_CR139","volume-title":"Endotext","author":"L Tannock","year":"2000","unstructured":"Tannock L (2000) Dyslipidemia in chronic kidney disease. In: De Groot LJ et al (eds) Endotext. MDText.com, Inc., South Dartmouth (MA)"},{"issue":"1","key":"2047_CR140","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.krcp.2012.12.001","volume":"32","author":"H Jin Kang","year":"2013","unstructured":"Jin Kang H et al (2013) Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease. Kidney Res Clin Pract 32(1):21\u201326","journal-title":"Kidney Res Clin Pract"},{"issue":"6","key":"2047_CR141","first-page":"963","volume":"57","author":"JH Ix","year":"2011","unstructured":"Ix JH et al (2011) Sustained hypophosphatemic effect of once-daily niacin\/laropiprant in dyslipidemic CKD stage 3 patients. Am J Kidney Dis 57(6):963\u2013965","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2047_CR142","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.05440517","volume":"13","author":"R Malhotra","year":"2018","unstructured":"Malhotra R et al (2018) The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol 13(1):36\u201344","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"2047_CR143","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.jacc.2008.03.025","volume":"51","author":"CR Harper","year":"2008","unstructured":"Harper CR, Jacobson TA (2008) Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 51(25):2375\u20132384","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2047_CR144","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/ki.2014.383","volume":"87","author":"RS Kalil","year":"2015","unstructured":"Kalil RS et al (2015) Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int 87(6):1250\u20131257","journal-title":"Kidney Int"},{"key":"2047_CR145","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12916-015-0503-4","volume":"13","author":"RM Stoekenbroek","year":"2015","unstructured":"Stoekenbroek RM, Kastelein JJ, Huijgen R (2015) PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Med 13:258","journal-title":"BMC Med"},{"issue":"2","key":"2047_CR146","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40265-017-0858-2","volume":"78","author":"B Zheng-Lin","year":"2018","unstructured":"Zheng-Lin B, Ortiz A (2018) Lipid management in Chronic Kidney Disease: systematic review of PCSK9 targeting. Drugs 78(2):215\u2013229","journal-title":"Drugs"},{"key":"2047_CR147","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","volume":"15","author":"PP Toth","year":"2016","unstructured":"Toth PP et al (2016) Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis 15:28","journal-title":"Lipids Health Dis"},{"issue":"6","key":"2047_CR148","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.kint.2018.01.030","volume":"93","author":"M Mafham","year":"2018","unstructured":"Mafham M, Haynes R (2018) PCSK9 inhibition: ready for prime time in CKD? Kidney Int 93(6):1267\u20131269","journal-title":"Kidney Int"},{"issue":"9","key":"2047_CR149","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/eci.12661","volume":"46","author":"U Elewa","year":"2016","unstructured":"Elewa U et al (2016) PCSK9 in diabetic kidney disease. Eur J Clin Invest 46(9):779\u2013786","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"2047_CR150","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/ckj\/sfv099","volume":"8","author":"FC Barcellos","year":"2015","unstructured":"Barcellos FC et al (2015) Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clin Kidney J 8(6):753\u2013765","journal-title":"Clin Kidney J"},{"issue":"4","key":"2047_CR151","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/ckj\/sfx006","volume":"10","author":"EM Miele","year":"2017","unstructured":"Miele EM et al (2017) High-density lipoprotein particle pattern and overall lipid responses to a short-term moderate-intensity aerobic exercise training intervention in patients with chronic kidney disease. Clin Kidney J 10(4):524\u2013531","journal-title":"Clin Kidney J"},{"key":"2047_CR152","doi-asserted-by":"publisher","first-page":"767424","DOI":"10.1155\/2014\/767424","volume":"2014","author":"B Afsar","year":"2014","unstructured":"Afsar B et al (2014) An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014:767424","journal-title":"Int J Nephrol"},{"issue":"1","key":"2047_CR153","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12944-018-0742-4","volume":"17","author":"H Shen","year":"2018","unstructured":"Shen H et al (2018) Effects of statin therapy on chronic kidney disease patients with coronary artery disease. Lipids Health Dis 17(1):84","journal-title":"Lipids Health Dis"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-018-2047-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-2047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-2047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:05:47Z","timestamp":1775293547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-018-2047-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":153,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["2047"],"URL":"https:\/\/doi.org\/10.1007\/s11255-018-2047-y","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"assertion":[{"value":"15 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}